Elan Corporation

Elan’s Board Unanimously Rejects Royalty Pharma’s Revised Offer

Elan Corporation, plc (NYSE:ELN) today announced that its board of directors has rejected a revised bid from privately held investment firm Royalty Pharma.

Irish biotechnology firm Elan Corporation, plc (NYSE:ELN) said its board has rejected the offer from Royalty Pharma, through its subsidiary Echo Pharma Acquisition Ltd, to acquire all of the shares of Elan Corporation, plc (NYSE:ELN) for $13.00 plus up to an additional $2.50 per share in contingent voting rights (CVR).

What . . .


This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here

If you are subscribed and having an account error please clear cache and then cookies if that does not work email support@valuewalk.com and we will get back to you as quick as humanly possible

Subscribe to our mailing list

* indicates required

Opt out of occasional 3rd party offers

Congrats! We have a limited time offer for loyal readers like yourself.

Sign up today and get three months free if you select yearly subscription

Use coupon code 3monthsfreeconfidential at checkout

Limited time offer only expires 3/31/2019 or next 30 subscribers whichever comes first – please do not share this discount with others